UroGen Pharma Ltd. (URGN) Gross Margin
- Gross margin · 12 months: Value 90.85%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 90.85% | Gross profit / revenue. Period ending 2026-06-30. $171.46M ÷ $188.73M × 100 ≈ 90.85% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 171.46M USD | Gross Profit |
| Revenue | 188.73M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $171.46M | $188.73M | (m) | 90.85% |
| 2026-03-31 | $126.24M | $140.49M | (m) | 89.85% |
| 2025-12-31 | $97.34M | $109.79M | (m) | 88.66% |
| 2025-09-30 | $84.89M | $96.52M | (m) | 87.95% |
| 2025-06-30 | $83.43M | $94.24M | (m) | 88.54% |
| 2025-03-31 | $82.39M | $91.87M | (m) | 89.68% |
| 2024-12-31 | $81.52M | $90.40M | (m) | 90.18% |
| 2024-09-30 | $80.67M | $89.36M | (m) | 90.27% |
| 2024-06-30 | $76.40M | $85.01M | (m) | 89.87% |
| 2024-03-31 | $75.48M | $84.30M | (m) | 89.53% |
| 2023-12-31 | $73.35M | $82.71M | (m) | 88.68% |
| 2023-09-30 | $67.94M | $77.28M | (m) | 87.92% |
| 2023-06-30 | $63.53M | $72.52M | (m) | 87.60% |
| 2023-03-31 | $59.59M | $67.98M | (m) | 87.65% |
| 2022-12-31 | $56.70M | $64.36M | (m) | 88.11% |
| 2022-09-30 | $55.46M | $62.44M | (m) | 88.82% |
| 2022-06-30 | $51.49M | $57.69M | (m) | 89.25% |
| 2022-03-31 | $48.34M | $54.12M | (m) | 89.31% |
| 2021-12-31 | $42.88M | $48.04M | (m) | 89.27% |
| 2021-09-30 | $35.61M | $39.83M | (m) | 89.41% |
| 2021-06-30 | $28.66M | $31.94M | (m) | 89.72% |
| 2021-03-31 | $17.38M | $19.28M | (m) | 90.12% |
| 2020-12-31 | $10.79M | $11.80M | (m) | 91.45% |
| 2020-09-30 | $3.48M | $3.83M | (m) | 90.69% |
| 2020-06-30 | $324.00K | $372.00K | (m) | 87.10% |
| 2019-12-31 | $18.00K | $18.00K | (m) | 100.00% |
| 2019-09-30 | $18.00K | $18.00K | (m) | 100.00% |
| 2019-06-30 | $-754.00K | $301.00K | (m) | -250.50% |
| 2018-12-31 | $-675.00K | $1.13M | (m) | -59.84% |
| 2018-09-30 | $-635.00K | $1.46M | (m) | -43.64% |
| 2018-06-30 | $7.65M | $8.98M | (m) | 85.20% |
| 2018-03-31 | $7.61M | $8.62M | (m) | 88.26% |
| 2017-12-31 | $7.56M | $8.16M | (m) | 92.65% |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) |
| 2016-12-31 | $17.50M | $17.53M | (m) | 99.84% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |